Eric Karas Biography and Net Worth

Chief Commercial Officer of ARS Pharmaceuticals

Eric Karas has served as our Chief Commercial Officer since April 2022. From 2018 to March 2022, Mr. Karas served as Vice President and General Manager of Commercial, North America at Emergent BioSolutions Inc. (NYSE: EBS). Prior to that, from 2016 to 2018, Mr. Karas led commercial initiatives for NARCAN^® Nasal Spray at Adapt Pharma, Inc., which was acquired by Emergent BioSolutions in 2018. Prior to Adapt Pharma, Mr. Karas spent eight years at Auxilium Pharmaceuticals, Inc. overseeing all global commercial objectives related to its urology portfolio. He also led the launch readiness planning and go-to-market strategy for the launch of XIAFLEX^® for Peyronie’s disease. Auxilium Pharmaceuticals was acquired in 2015 by Endo International plc (Nasdaq: ENDP). Mr. Karas has also held cross-functional roles in government affairs, public relations, patient advocacy and sales leadership roles at Astellas Pharma Inc., Bristol-Myers Squibb Company (NYSE: BMY) and Merck & Co., Inc. (NYSE: MRK). Industry associations have recognized him for numerous disease awareness and branded campaigns targeting healthcare professionals and consumers. Mr. Karas received his M.B.A. in integrated management from Michigan State University, Broad School of Management, and a B.S. in accounting from Rutgers University.

What is Eric Karas' net worth?: The estimated net worth of Eric Karas is at least $99,432.32 as of March 20th, 2025. Mr. Karas owns 7,696 shares of ARS Pharmaceuticals stock worth more than $99,432 as of March 24th. This net worth estimate does not reflect any other assets that Mr. Karas may own. Additionally, Mr. Karas receives a salary of $618,610.00 as Chief Commercial Officer at ARS Pharmaceuticals. Learn More about Eric Karas' net worth.
How old is Eric Karas?: Mr. Karas is currently 51 years old. There are 6 older executives and no younger executives at ARS Pharmaceuticals. The oldest executive at ARS Pharmaceuticals is Mr. Harris Kaplan M.B.A., Executive Vice President of Commercial Strategy, who is 72 years old. Learn More on Eric Karas' age.
What is Eric Karas' salary?: As the Chief Commercial Officer of ARS Pharmaceuticals, Inc., Mr. Karas earns $618,610.00 per year. There are 3 executives that earn more than Mr. Karas. The highest earning executive at ARS Pharmaceuticals is Mr. Richard Lowenthal M.B.A., M.S., MSMSEL, Founder, President, CEO & Director, who commands a salary of $2,750,000.00 per year. Learn More on Eric Karas' salary.
How do I contact Eric Karas?: The corporate mailing address for Mr. Karas and other ARS Pharmaceuticals executives is 500 Fairview Ave N Suite 600, Seattle WA, 98109. ARS Pharmaceuticals can also be reached via phone at 206-456-2900 and via email at ir@silverbacktx.com. Learn More on Eric Karas' contact information.
Has Eric Karas been buying or selling shares of ARS Pharmaceuticals?: During the past quarter, Eric Karas has sold $140,000.00 in shares of ARS Pharmaceuticals stock. Most recently, Eric Karas sold 10,000 shares of the business's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $14.00, for a transaction totalling $140,000.00. Following the completion of the sale, the insider now directly owns 7,696 shares of the company's stock, valued at $107,744. Learn More on Eric Karas' trading history.
Who are ARS Pharmaceuticals' active insiders?: ARS Pharmaceuticals' insider roster includes Justin Chakma (Chief Business Officer), Brian Dorsey (Chief Operating Officer), Alexander Fitzpatrick (Chief Legal Officer), Eric Karas (Chief Commercial Officer), Richard Lowenthal (President and Chief Executive Officer), Kathleen Scott (Chief Financial Officer), Laura Shawver (Director), Sarina Tanimoto (Chief Medical Officer), and Peter Thompson (Director). Learn More on ARS Pharmaceuticals' active insiders.
Are insiders buying or selling shares of ARS Pharmaceuticals?: In the last twelve months, ARS Pharmaceuticals insiders bought shares 2 times. They purchased a total of 943,554 shares worth more than $8,917,945.66. In the last twelve months, insiders at the sold shares 38 times. They sold a total of 3,056,320 shares worth more than $40,365,109.22. The most recent insider tranaction occured on March, 20th when insider Eric Karas sold 10,000 shares worth more than $140,000.00. Insiders at ARS Pharmaceuticals own 40.1% of the company. Learn More about insider trades at ARS Pharmaceuticals.
Information on this page was last updated on 3/20/2025.

Eric Karas Insider Trading History at ARS Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/20/2025	Sell	10,000	$14.00	$140,000.00	7,696
9/18/2024	Sell	10,000	$14.00	$140,000.00	5,693
8/19/2024	Sell	10,000	$14.00	$140,000.00	5,693

Eric Karas Buying and Selling Activity at ARS Pharmaceuticals

ARS Pharmaceuticals Company Overview

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Today's Range

Now: $12.89

$12.08

$12.99

50 Day Range

MA: $12.10

$10.18

$14.88

2 Week Range

Now: $12.89

$7.55

$18.51

Volume

4,073,338 shs

Average Volume

1,063,646 shs

Market Capitalization

$1.25 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

Eric Karas Biography and Net Worth

What is Eric Karas' net worth?

How old is Eric Karas?

What is Eric Karas' salary?

How do I contact Eric Karas?

Has Eric Karas been buying or selling shares of ARS Pharmaceuticals?

Who are ARS Pharmaceuticals' active insiders?

Are insiders buying or selling shares of ARS Pharmaceuticals?